際際滷

際際滷Share a Scribd company logo

The Therapeutic Potential of Resveratrol- A Review of Clinical Trials

Download as PPTX, PDF
NDMVP College of Pharmacy Nashik
NDMVP College of Pharmacy Nashik

Various Potential Uses of Resveratrol in different diseases such as Cancer, Alzhiemers, Coronary Artery Disease, Ischemic Stroke, Atherosclerosis, Hypertension, Oxidative Stress, Type 2 Diabetes, Impaired Glucose Tolerance, Non Alcoholic fatty liver disease, Neurological Disorders

1 of 8
Download to read offline
The Therapeutic Potential of Resveratrol - A Review of Clinical Trials PRESENTED BY GUIDANCE BY DANISH SAYYAD Dr. A.P. PINGLE Quality Assurance Techniques Dept. Pharmaceutical Chemistry FIRST YEAR M.PHARM Roll no - 09 NDMVP SAMAJS COLLEGE OF PHARMACY, NASHIK. 1
Sources include the skin of grapes, blueberries, raspberries, mulberries, and peanuts. It is a Stilbenoid (C6-C2-C6) It is a Phytoalexin It is a Solution to French Paradox It is a Neutraceutical
Chemo preventive and Chemotherapeutic Effects all 3 stages of carcinogenesis i.e. Initiation, Promotion and Progression Induce Apoptosis pathway Affects Nuclear factor 虜B (NF-虜B) Inhibits IGF-1R (hypertrophy) and activate P53 (Tumor Protein) Inhibits phosphatidyl-inositol-3- kinase(PI3K)/Protein kinase B (Akt)/mTOR pathway
The Therapeutic Potential of Resveratrol- A Review of Clinical Trials
Inhibits cyclooxygenases (COX) anti inflammatory Inhibits Vascular cell adhesion molecules (VCAM) that affects activity of smooth muscles cells which are responsible for the development of atherosclerosis and hypertension Inhibits Platelet aggregation and prevent blood clot formation Anti Aging - Activation of longevity gene (Sirtuins) Pharmacokinetics More effective topically rather orally (quickly metabolized and excreted)
The Therapeutic Potential of Resveratrol- A Review of Clinical Trials
References 1. Adi Y. Berman, Rachel A. Motechin, Maia Y. Wiesenfeld and Marina K. Holz, The therapeutic potential of resveratrol: a review of clinical Trials, Nature precision oncology, nature publications, 1-9 (2017) 2. Chung, S. et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501, 7990 (2010). 3. Magyar, K. et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50, 179187(2012). 4. Paller, C. J. et al. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: safety, tolerability, and dose determination. Prostate 75, 15181525 (2015).
5. Pasinetti, G. M., Wang, J., Ho, L., Zhao, W. & Dubner, L. Roles of resveratrol and other grape-derived polyphenols in Alzheimers disease prevention and treatment. Biochim. Biophys. Acta 1852, 12021208 (2015). 6. Chen, J., Bai, Q., Zhao, Z., Sui, H. & Xie, X. Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol. Scand. 134, 5460 (2016). 7. Alayev, A., Berger, S. M., Kramer, M. Y., Schwartz, N. S. & Holz, M. K. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 116, 450457 (2015). 8. David A. Sinclair. A conserved NAD binding pocket that regulates protein-protein interactions during aging. Science, 24 Mar 2017: Vol. 355, Issue 6331, pp. 1312-1317.

More Related Content

The Therapeutic Potential of Resveratrol- A Review of Clinical Trials

  • 1. The Therapeutic Potential of Resveratrol - A Review of Clinical Trials PRESENTED BY GUIDANCE BY DANISH SAYYAD Dr. A.P. PINGLE Quality Assurance Techniques Dept. Pharmaceutical Chemistry FIRST YEAR M.PHARM Roll no - 09 NDMVP SAMAJS COLLEGE OF PHARMACY, NASHIK. 1
  • 2. Sources include the skin of grapes, blueberries, raspberries, mulberries, and peanuts. It is a Stilbenoid (C6-C2-C6) It is a Phytoalexin It is a Solution to French Paradox It is a Neutraceutical
  • 3. Chemo preventive and Chemotherapeutic Effects all 3 stages of carcinogenesis i.e. Initiation, Promotion and Progression Induce Apoptosis pathway Affects Nuclear factor 虜B (NF-虜B) Inhibits IGF-1R (hypertrophy) and activate P53 (Tumor Protein) Inhibits phosphatidyl-inositol-3- kinase(PI3K)/Protein kinase B (Akt)/mTOR pathway
  • 5. Inhibits cyclooxygenases (COX) anti inflammatory Inhibits Vascular cell adhesion molecules (VCAM) that affects activity of smooth muscles cells which are responsible for the development of atherosclerosis and hypertension Inhibits Platelet aggregation and prevent blood clot formation Anti Aging - Activation of longevity gene (Sirtuins) Pharmacokinetics More effective topically rather orally (quickly metabolized and excreted)
  • 7. References 1. Adi Y. Berman, Rachel A. Motechin, Maia Y. Wiesenfeld and Marina K. Holz, The therapeutic potential of resveratrol: a review of clinical Trials, Nature precision oncology, nature publications, 1-9 (2017) 2. Chung, S. et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501, 7990 (2010). 3. Magyar, K. et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50, 179187(2012). 4. Paller, C. J. et al. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: safety, tolerability, and dose determination. Prostate 75, 15181525 (2015).
  • 8. 5. Pasinetti, G. M., Wang, J., Ho, L., Zhao, W. & Dubner, L. Roles of resveratrol and other grape-derived polyphenols in Alzheimers disease prevention and treatment. Biochim. Biophys. Acta 1852, 12021208 (2015). 6. Chen, J., Bai, Q., Zhao, Z., Sui, H. & Xie, X. Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol. Scand. 134, 5460 (2016). 7. Alayev, A., Berger, S. M., Kramer, M. Y., Schwartz, N. S. & Holz, M. K. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 116, 450457 (2015). 8. David A. Sinclair. A conserved NAD binding pocket that regulates protein-protein interactions during aging. Science, 24 Mar 2017: Vol. 355, Issue 6331, pp. 1312-1317.